These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4395168)

  • 1. N-(perhydroazepinoalkynyl)- and N-(perhydroazocinoalkynyl) succinimides as oxotremorine antagonists.
    Lindqvist A; Lindgren S; Lindeke B; Karlén B; Dahlbom R; Blair MR
    J Pharm Pharmacol; 1970 Sep; 22(9):707-8. PubMed ID: 4395168
    [No Abstract]   [Full Text] [Related]  

  • 2. Acetylene compounds of potential pharmacological value. XVI. N-(perhydroazepinoalkynyl)- and N-(perhydroazocinoalkynyl)succinimides.
    Lindquist A; Lindgren S; Lindeke B; Karlén B; Dahlbom R; Blair MR
    Acta Pharm Suec; 1972 Apr; 9(2):93-8. PubMed ID: 5030544
    [No Abstract]   [Full Text] [Related]  

  • 3. Acetylene compounds of potential pharmacological value. XIX. N-(dialkylaminoalkynyl)-substituted succinimides and 2-pyrrolidones as partial cholinergic agonists.
    Svensson U; Dahlbom R
    Acta Pharm Suec; 1975; 12(3):209-14. PubMed ID: 1163240
    [No Abstract]   [Full Text] [Related]  

  • 4. Acetylene compounds of potential pharmacological value. XXX. Synthesis and pharmacological properties of N-(4-pyrrolidino-2-pentynyl)-substituted 2-pyrrolidone and succinimide.
    Resul B; Ringdahl B; Dahlbom R
    Acta Pharm Suec; 1979; 16(3):161-5. PubMed ID: 484249
    [No Abstract]   [Full Text] [Related]  

  • 5. Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones.
    Amstutz R; Ringdahl B; Karlén B; Roch M; Jenden DJ
    J Med Chem; 1985 Dec; 28(12):1760-5. PubMed ID: 2933518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylene compounds of potential pharmacological value. XXIX. Stereoselectivity of N-(1-alkyl-4-pyrrolidino-2-butynyl)-substituted 2-pyrrolidones and succinimides as oxotremorine antagonists.
    Ringdahl B; Dahlbom R
    Acta Pharm Suec; 1979; 16(1):13-20. PubMed ID: 452907
    [No Abstract]   [Full Text] [Related]  

  • 7. Acetylene compounds of potential pharmacological value. 18. N-(t-aminoalkynyl)-substituted 2-pyrrolidones, a new series of potent oxotremorine antagonists.
    Lindgren S; Lindquist A; Lindeke B; Svensson U; Karlén B; Dahlbom R
    Acta Pharm Suec; 1973 Dec; 10(6):435-40. PubMed ID: 4773112
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclopropane analogues to acetylenic oxotremorine antagonists.
    Grundström K; Dahlbom R
    Acta Pharm Suec; 1972 Nov; 9(5):491-8. PubMed ID: 4650125
    [No Abstract]   [Full Text] [Related]  

  • 9. N-(t-aminoalkynyl)-substituted pyrrolidones as oxotremorine antagonists.
    Lindgren S; Lindquist A; Lindeke B; Svensson U; Karlén B; Dahlbem R; Blair MR
    Experientia; 1970 Nov; 26(11):1232-3. PubMed ID: 5485292
    [No Abstract]   [Full Text] [Related]  

  • 10. The central and peripheral effectiveness of two oxotremorine-antagonists determined using oxotremorine-induced tremor and salivation.
    Eicholzer A; Ogren SO
    J Pharm Pharmacol; 1977 Oct; 29(10):609-11. PubMed ID: 21240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oxotremorine and atropine on cGMP and cAMP levels in mouse cerebral cortex and cerebellum.
    Ferrendelli JA; Steiner AL; McDougal DB; Kipnis DM
    Biochem Biophys Res Commun; 1970 Nov; 41(4):1061-7. PubMed ID: 4320068
    [No Abstract]   [Full Text] [Related]  

  • 12. Duration of effect of atropine sulphate against the toxicity of oxotremorine in mice.
    Natoff IL
    J Pharm Pharmacol; 1970 Feb; 22(2):133-4. PubMed ID: 4392250
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of distribution as a determinant of central anticholinergic specificity in a series of oxotremorine analogs.
    Karlén B; Jenden DJ
    Res Commun Chem Pathol Pharmacol; 1970 Jul; 1(4):471-8. PubMed ID: 5524258
    [No Abstract]   [Full Text] [Related]  

  • 14. Acetylene compounds of potential pharmacological value. XXI. Further studies on the effect of branching the intermediate chain of N-(t-aminoalkynyl)-substituted succinimides and 2-pyrrolidones.
    Ringdahl B; Svensson U; Dahlbom R
    Acta Pharm Suec; 1975; 12(4):297-304. PubMed ID: 1199731
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and pharmacology of N-(4-diethylamino-2-butynyl)-succinimide (DKJ 21), a new central anticholinergic agent.
    Dahlbom R; Karlen B; George R; Jenden DJ
    Life Sci; 1966 Sep; 5(17):1625-31. PubMed ID: 5970685
    [No Abstract]   [Full Text] [Related]  

  • 16. Investigation of central cholinergic mechanisms in the conscious mouse.
    Ankier SI; Brittain RT; Jack D
    Br J Pharmacol; 1971 May; 42(1):127-36. PubMed ID: 5580697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscarinic actions of an N-methyl-N-2-bromoethylamino analog of oxotremorine (BR 401) in the mouse.
    Ringdahl B; Jenden DJ
    J Pharmacol Exp Ther; 1987 Feb; 240(2):370-5. PubMed ID: 3806401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the mechanism of action of oxotremorine on the guinea-pig isolated ileum preparation.
    Cox B; Hecker SE
    Br J Pharmacol; 1971 Jan; 41(1):19-25. PubMed ID: 5547759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxotremorine-induced hypertension in the anaesthetized rat.
    Walker JL; Weetman DF
    Br J Pharmacol; 1970 Jul; 39(3):490-500. PubMed ID: 5273193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of oxotremorine lethality by antihistamines.
    Gerald MC; Maickel RP
    J Pharm Pharmacol; 1970 May; 22(5):361-5. PubMed ID: 4392994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.